**Title:** Prospective assessment of catheter-associated bacteriuria in nursing home residents:

clinical presentation, epidemiology, and colonization dynamics

**Running title:** Epidemiology of catheter-associated bacteriuria

**Authors:** Chelsie E. Armbruster[1#],Aimee L. Brauer[1], Monica S. Humby[1]

**Affiliations:** [1]Department of Microbiology and Immunology, Jacobs School of Medicine and

Biomedical Sciences, State University of New York at Buffalo

#Corresponding author:

Chelsie E. Armbruster: chelsiea@buffalo.edu

**Abstract** (249/250 words)

Background: Long-term catheterization facilitates continuous bacteriuria, for which the clinical significance is unclear. The objectives of this study were to determine the clinical presentation, epidemiology, and dynamics of bacteriuria in a cohort of catheterized nursing home residents.

Methods: Prospective weekly urine collection, culture, urinalysis, chart review, and assessment of possible signs and symptoms of infection for 19 study participants over 260 weeks. All bacteria $\geq 10^3$ cfu/ml were isolated, identified, and subjected to select antimicrobial testing.

Results: From 234 urine samples, 1,092 bacteria were isolated and 286 (26%) were resistant to a tested antimicrobial. 226 urines were polymicrobial (97%), with an average of 4.7 isolates per weekly specimen. 233 urines (99%) exhibited $>10^3$ CFU/ml, 220 (94%) exhibited abnormal urinalysis, 77 (33%) were associated with at least one sign or symptom of infection, 51 (22%) met a standardized definition of CAUTI, and 3 (1%) had a corresponding caregiver diagnosis of CAUTI. Bacteriuria composition was remarkably stable, but catheter changes and antimicrobial treatment resulted in a net increase of 1.9 and 0.3 isolates per participant, respectively, and represented a source of new acquisition of antimicrobial resistant bacteria.

Conclusions: Catheterized individuals exhibit a high baseline prevalence of bacteriuria involving pathogenic bacteria and potential indicators of infection. Bacteriuria composition is largely polymicrobial and stable, and includes organisms previously considered to be urine culture contaminants. However, catheter changes and antimicrobial treatment may do more harm than good in this patient population.

37      Funding: This work was supported by the NIH (R00 DK105205, R01 DK123158, UL1

38      TR001412)

**Introduction**

Urinary catheter placement in healthcare settings is a common medical procedure utilized in the treatment of 60% of critically ill patients, 20% of those in medical and surgical intensive care units, and 5-22% of residents in long-term care facilities (1-6). This is particularly true in nursing homes, where 12-15% of newly-admitted individuals have an indwelling urinary catheter and 5-10% have a chronic urinary catheter for indications such as chronic pressure ulcers or wounds, traumatic pelvic injury, neurogenic bladder, and having low overall functional status (4, 7, 8). These individuals are also more likely to have a urinary catheter in place for prolonged periods of time, which doubles the risk of developing symptomatic catheter-associated urinary tract infection (CAUTI) and provides a reservoir for antimicrobial resistant bacteria (8-10).

Indwelling urinary catheters facilitate the presence of bacteria in urine (bacteriuria) within 5-7 days after placement (11), bypassing many of the natural defenses of the urinary tract by providing a route of entry for bacteria that would normally be prevented from colonizing the bladder. Bacteria that colonize the periurethral area are typically excluded from the urinary tract by a combination of micturition (the regular passing of urine), the physical barrier provided by intact urothelial cells along with the mucin they produce, and by innate immune defenses. However, insertion of a catheter damages the urothelial barrier, disrupts normal micturition, and results in retention of a low volume of urine within the bladder, all of which facilitate bacterial growth (12-14). The immune response elicited by the catheter also results in accumulation of host proteins such as fibrinogen, which prime the catheter surface and facilitate bacterial attachment (15-17). The combination of these factors creates a uniquely permissive environment for numerous bacterial species to colonize and potentially establish infection. Indeed, for each day that a urinary catheter is in place, there is a 3-8% incidence of bacteriuria, and long-term

catheterization (>28 days) typically results in continuous bacteriuria and symptomatic CAUTI (1,

18).

Catheterization and resulting bacteriuria are associated with numerous adverse outcomes,

such as functional decline, increased hospital stays, inappropriate or inadequate antimicrobial

treatment, and nearly double the mortality rate compared to non-catheterized individuals (1, 6,

18-23). However, catheter-associated bacteriuria is frequently asymptomatic and can be

challenging to distinguish from CAUTI, especially in long-term care settings. Guidelines for

diagnosis of CAUTI include the presence of clinical signs and symptoms in addition to a positive

urine culture (24-26). For instance, the 2010 clinical care guidelines of the Infectious Diseases

Society of America (IDSA) define CAUTI as a positive urine culture ($\geq 10^3$ CFU/ml of $\geq 1$

bacterial species) combined with signs or symptoms compatible with UTI (fever, rigors, altered

mental status, malaise or lethargy with no other identified cause, flank pain, costovertebral

tenderness, acute hematuria, or pelvic discomfort) in the absence of an alternate source of

infection (1, 27). In the absence of these symptoms, a culture with $\geq 10^5$ CFU/ml of $\geq 1$ bacterial

species is considered asymptomatic catheter-associated bacteriuria (1). In contrast, the National

Health Safety Network (NHSN) surveillance criteria for long-term care facilities define

symptomatic CAUTI as having a positive urine culture (no more than 2 species, of which at least

one must be a bacterium at $\geq 10^5$ CFU/ml of urine) combined with at least one of the following:

a) fever (single temperature >100°F, repeated temperatures >99°F, or an increase of >2°F over

baseline), b) rigors, c) new onset hypotension (<90 systolic or <60 diastolic blood pressure)

without an alternate non-infectious cause, d) new onset decline in mental or functional status

combined with leukocytosis (>14,000 leukocytes/mm$^3$) and without an alternate diagnosis, e)

new or increased suprapubic tenderness, f) new or increased costovertebral pain or tenderness, h)

acute pain, swelling, or tenderness of the testes, epididymis, or prostate, or h) purulent discharge

from the catheter insertion site (25, 28).

Diagnosis of CAUTI is particularly challenging in older adults, especially those with

neurogenic bladder, cognitive impairments, or a high degree of functional dependence. In this

population, CAUTI is often a "diagnosis of exclusion" as many signs and symptoms of infection

(such as fever and leukocytosis) are infrequent or absent while other signs of infection may be

subtle or non-specific (29-38). A further confounding issue is the high prevalence of acute metal

status change and confusion in this population (31, 36, 39), coupled with issues regarding

reliable assessment of mental status and other non-specific symptoms (40). To reduce

inappropriate antimicrobial treatment, development of antimicrobial resistance, and risk of

*Clostridioides difficile* infection, the 2019 guidelines of the IDSA strongly recommend against

screening for or treating asymptomatic bacteriuria in older, functionally or cognitively impaired

adults, especially those residing in long-term care facilities, as well as individuals with

indwelling urinary catheters (27). The guidelines further indicate that mental status change and

bacteriuria without local genitourinary symptoms or systemic symptoms should not be

considered to indicate symptomatic UTI in older, functionally or cognitively impaired adults

(27). However, non-specific symptoms, such as change in mental status and confusion, are the

most common indications for suspected UTI in nursing home residents and antimicrobial

prescription for asymptomatic bacteriuria remains common in this population (31, 41).

While several studies have reported the epidemiology of bacteriuria in catheterized

individuals (1, 2, 31, 42-54), few have conducted a longitudinal assessment of colonization

dynamics or included prospective assessment of infection signs and symptoms to clearly

differentiate between asymptomatic colonization and CAUTI. These collective studies have also

demonstrated that polymicrobial bacteriuria and CAUTI are common during long-term

catheterization, yet few report the full etiology of polymicrobial urine cultures. To address these

gaps in knowledge, we conducted a prospective longitudinal assessment of bacteriuria in

catheterized nursing home residents from two facilities in New York. Our study had three

primary goals: 1) determine the clinical presentation of catheter-associated bacteriuria and

CAUTI in catheterized nursing home residents, 2) determine the epidemiology of catheter-

associated bacteriuria and CAUTI, including carriage of antimicrobial resistant bacteria, and 3)

determine the impact of disruptions, such as catheter changes and antimicrobial treatment, on

colonization dynamics.

**Results**

**Description of Study Population**

A total of 19 nursing home residents with long-term indwelling urinary catheters (≥1 year) were enrolled at two facilities in Buffalo, New York to monitor the prevalence, epidemiology, and clinical presentation of bacteriuria on a weekly basis for up to 7 months. As summarized in Table 1, the majority of the study participants were white (79%), male (79%), and had suprapubic catheters (68%). Study participants exhibited a high level of functional dependence for activities of daily living, as indicated by an average physical self-maintenance score (PSMS) of 22 on a scale ranging from 6-30 (55). The most common comorbidities were neurogenic bladder (74%), hemiplegia (42%), diabetes (32%), renal disease (32%), multiple sclerosis (26%), and chronic heart failure (26%).

Study participants were followed for a total of 260 patient-weeks (13 average, range 1-30), with 9 of the 19 participants completing greater than 12 weeks of follow-up. Including baseline samples, 234 urine cultures were collected during the study, with an average of 12 per participant (range 1-28). Ten participants (53%) had catheter changes during the study, for a combined total of 50 catheter changes (5 average, range 1-12). Four participants (21%) experienced a combined total of 8 caregiver-diagnosed infections during follow-up, of which 3 were reported as CAUTI in the participant's medical charts. Seven participants (37%) received antimicrobial treatment during the course of follow-up, for a total of 20 patient-weeks of antimicrobial use, including 2 participants who received antimicrobial treatment for 3 CAUTIs.

**Clinical Presentation of Catheter-Associated Bacteriuria**

Potential signs and symptoms of infection were prospectively assessed and collected

form participant medical records at all study visits to determine point prevalence at baseline,

weekly prevalence, and incidence (Table 2). This assessment included non-specific signs and

symptoms, such as nausea, lack of appetite, and fatigue, to gauge malaise and lethargy as

components of the IDSA CAUTI definition. The most common clinical presentations at baseline

were altered mental status (5/19 participants, 26%), hypotension (4/19, 21%), fatigue (4/19,

21%), suprapubic or costovertebral pain or tenderness (3/19, 16%), and lack of appetite (3/19,

16%). Hypotension, fatigue, altered mental status, and lack of appetite exhibited the highest

weekly prevalence and incidence, while fever, chills, and leukocytosis were less common and

typically only present at a single study visit. As noted above, only 3 caregiver-diagnosed

CAUTIs occurred during the course of the study, yet 16/19 participants (84%) had a combined

51 study visits at which the IDSA CAUTI definition (1, 27) was met and no alternate source of

signs or symptoms was identified, including the 3 diagnosed CAUTIs. The most common

clinical presentations for visits meeting the IDSA CAUTI definition were new onset hypotension

(21/51 cases, 41%), new onset acute mental status change (19/51, 37%), new onset malaise

(12/51, 23%), new or worsening suprapubic or costovertebral pain or tenderness (10/51, 20%),

and fever (9/51, 18%).

Notably, only 12 study visits met the more strict NHSN surveillance definition (25, 28).

The main contributors to this reduction are the stringent cutoff of ≤ 2 organisms in the urine

culture, and the requirement that mental status change must be accompanied by leukocytosis

(which was not prospectively assessed and only reported in the medical records of three study

participants). Importantly, none of the 3 caregiver-diagnosed CAUTIs would meet the NHSN

surveillance criteria as all 3 involved >2 organisms. However, 2 of the 3 diagnosed CAUTIs

involved bacteremia with one of the bacterial species present in urine, indicating that these cases

likely represent true CAUTI. When urine cultures containing 3 or more organisms are permitted

for the NHSN criteria, the number of visits that would meet the NHSN CAUTI surveillance

definition increases to 40 and includes all 3 caregiver-diagnosed CAUTIs. Altogether,

prospective weekly assessment of possible signs and symptoms revealed that numerous potential

indicators of infection are common in catheterized nursing home residents and fluctuate in

duration, which may further confound the utility of these indicators for distinguishing CAUTI

from asymptomatic bacteriuria in this patient population.

All urine samples were also subjected to urinalysis via 10-parameter urine reagent test

strip to determine the point prevalence of parameters that are often considered to be suggestive

of urinary tract infection, along with weekly prevalence and incidence (Table 3). The most

common urinalysis findings at baseline were the presence of leukocytes (17/19 participants,

89%), proteinuria (10/19, 53%), nitrites (10/19, 53%), and hematuria (8/19, 42%). The highest

weekly prevalence was observed for leukocytes, proteinuria, and nitrites. Leukocytes and high

pH were highly persistent and typically identified in multiple consecutive urine samples, while

hematuria and ketones were more likely to be present at a single study visit. Overall, 220 of the

234 urine samples (94%) had a urinalysis result that would be suggestive of infection in a non-

catheterized individual and could influence perception of urine culture results. Abnormal

urinalysis results were also present in 49/51 (96%) study visits at which the IDSA CAUTI

definition was met. Taken together, these data indicate that caution is required when interpreting

urinalysis results and possible signs and symptoms of urinary tract infection in nursing home

residents with long-term indwelling catheters, as there is a high baseline prevalence and weekly

prevalence of several indicators.

**Epidemiology of Catheter-Associated Bacteriuria**

A total of 234 urine cultures were collected during 260 study visits. Twenty-six cultures could not be obtained due to absence of the participant on a particular visit or the participant not wanting to be disturbed that day. Of the 234 urine cultures, 233 (99%) exhibited bacterial growth $>10^3$ colony forming units (CFU) per milliliter of urine, with an average of $5.12 \times 10^6$ CFU/ml (range $5.5 \times 10^4 - 6.2 \times 10^6$ CFU/ml). Notably, the only culture-negative urine was obtained while the study participant was receiving intravenous antimicrobials for CAUTI with bacteremia.

A total of 1,092 bacterial isolates were cultured from the 233 culture-positive urines, of which 623 (57%) were Gram-negative and 469 (43%) were Gram-positive (Tables 4 and 5). 286 isolates (26%) were resistant to at least one of the tested antimicrobial agents, confirming that catheter-associated bacteriuria is a significant reservoir of resistant bacteria in nursing homes. Consistent with this observation, urine specimens from 12 of the 19 participants (63%) contained at least one resistant organism (Table 5). All isolates that were resistant to ceftazidime were also resistant to ceftazidime with clavulanic acid, indicating production of an extended spectrum β-lactamase (ESBL). The most common resistances were to ciprofloxacin (exhibited by 171 of the 623 Gram-negative isolates [27%]), methicillin (81 of the 168 *Staphylococcus aureus* isolates [48%]), and production of ESBLs (37 of the 623 Gram-negative isolates [6%]). Notably, none of the Gram-negative isolates were resistant to imipenem, and none of the *Enterococcus* isolates were resistant to vancomycin.

Antimicrobial resistance was most prevalent for *Proteus mirabilis* (69% of isolates resistant to ciprofloxacin), *S. aureus* (48% resistant to methicillin), *Providencia stuartii* (44% resistant, 24% ciprofloxacin resistant and 20% ESBL), *Morganella morganii* (37% resistant to

ciprofloxacin), *Pseudomonas aeruginosa* (29% resistant, 18% ESBL and 15% ciprofloxacin

resistant), and *Escherichia coli* (29% resistant to ciprofloxacin) (Table 5). For most organisms,

all sequential isolates from a single participant exhibited the same colony morphology and

resistance profile, with the exception of *S. aureus*. Methicillin-resistant *S. aureus* (MRSA) is

therefore discussed separately from methicillin-sensitive *S. aureus* (MSSA).

The vast majority of culture-positive urines were polymicrobial (226/233, 97%), with an

average of 4.7 isolates per weekly urine specimen (range 1-10); 30 (13%) harbored two distinct

isolates, 24 (11%) had three isolates, 39 (17%) had four isolates, 52 (23%) had five isolates, 41

(18%) had six isolates, 18 (8%) had seven isolates, and 22 (9%) had eight or more distinct

isolates. As displayed in Table 4, the most common organisms at baseline were *Enterococcus*

*faecalis* (14/19 baseline urine specimens, 74%), *P. stuartii* (8/19, 42%), *E. coli* (7/19, 37%),

coagulase-negative *Staphylococcus* (7/19, 37%), and *P. mirabilis* 6/19, 32%). However, the

highest weekly prevalence was observed for *E. faecalis* (63%), *P. mirabilis* (45%), *P. stuartii*

(43%), miscellaneous PYR-negative Catalase-negative Gram-positive isolates (37%), and *S.*

*aureus* (33% for methicillin-sensitive isolates and 31% for methicillin-resistant isolates). The

most stable and persistent colonizers were *E. faecalis, P. mirabilis, P. stuartii,* and *E. coli,* while

organisms such as *P. aeruginosa, Providencia rettgeri, Klebsiella pneumoniae,* coagulase-

negative *Staphylococcus,* and *Serratia marsescens* tended to exhibit transient colonization.

Microbe-microbe interactions during polymicrobial colonization can have profound

implications for risk of developing severe disease (56-61). The most prevalent co-colonization

partners were therefore identified from each urine specimen (Supplemental Table 1), along with

the number of participants who exhibited each combination during at least one study visit

(Supplemental Table 2). The most common combinations were *E. faecalis* with *P. mirabilis*

(93/233 culture-positive urines [40%]; 9/19 participants [47%]), *E. faecalis* with *P. stuartii*

(86/233 [37%]; 8/19 [42%]), *E. faecalis* with *E. coli* (82/233 [35%]; 8/19 [42%]), *P. mirabilis*

with *P. stuartii* (80/233 [34%]; 8/19 [42%]), *E. faecalis* with MSSA (68/233 [29%]; 8/19 [42%]),

*E. faecalis* with MRSA (66/233 [28%]; 8/19 [42%]), *M. morganii* with *P. stuartii* (63/233 [27%];

5/19 [26%]),  and *E. faecalis* with *M. morganii* (61/233 [26%]; 5/19 [26%]). In contrast, some

combinations of organisms were rarely observed, such as MRSA with MSSA (12/233 [5%]; 3/19

[16%]), *E. coli* with coagulase-negative *Staphylococcus* (3/233 [1%]; 1/19 [5%]), *E. coli* with *P.*

*aeruginosa* (13/233 [6%]; 3/19 [16%]), *K. pneumoniae* with *P. stuartii* (13/233 [6%]; 2/19

[10%]), and *P. mirabilis* with *P. rettgeri* (8/233 [3%]; 3/19 [16%]).

**Colonization Dynamics**

To further explore the prevalence and dynamics of bacteriuria with each organism,

colonization was plotted on a per-participant basis (Figure 1). Overall, 18/19 participants (95%)

were colonized by *E. faecalis* during at least one study visit, 11/19 (58%) *P. mirabilis,* 11/19

(58%) coagulase-negative *Staphylococcus,* 9/19 (47%) *P. stuartii,* 9/19 (47%) MRSA, 9/19

(47%) MSSA, 8/19/19 (42%) *E. coli,* 8/19 (42%) *P. aeruginosa,* 5/19 (26%) *M. morganii,* and

5/19 (26%) *K. pneumoniae* (Table 5*)*. Consistent with the high percentage of polymicrobial

urines, the majority of the study participants exhibited polymicrobial bacteriuria during at least

one study visit (18/19, 95%): 15/19 (79%) exhibited polymicrobial bacteriuria at all weekly

visits, 3/19 (16%) mostly had polymicrobial specimens with one or two monomicrobial samples,

and one participant only exhibited monomicrobial urine samples (Figure 1).

For each study participant, the epidemiology of bacteriuria was remarkably consistent

across consecutive study visits. For the 9 study participants with at least 12 weeks of follow-up,

*E. faecalis* was isolated from an average of 20.4 consecutive urine specimens, *P. mirabilis* from

16.9, *E. coli* from 12.7, and *P. stuartii* from 10.1. In contrast, *P. vulgaris* and *Pseudomonas*

species exhibited intermittent colonization, and were typically detected in <4 consecutive urines

from each participant. Considering that all 9 study participants experienced at least one catheter

change or course of antimicrobial treatment, the impact of these events on colonization dynamics

were further investigated for all instances with at least three weeks of post-event follow-up

(Table 6).

Eight participants with at least 12 weeks of follow-up had an average of 5 catheter

changes each (range 2-11). Catheter changes resulted in a combined loss of 28 isolates, with an

average loss of 3.5 colonizing isolates per participant. However, 20 of the 28 isolates (71%) were

regained within the subsequent 4 weeks, indicating that catheter changes were not effective in

reducing bacteriuria. Strikingly, 23 new isolates were acquired after catheter changes, for an

average of 2.9 new isolates per participant gained from catheter changes. Altogether, catheter

changes resulted in a net increase of 1.9 isolates, indicating that changing the catheter was more

likely to introduce new organisms than reduce colonization by existing organisms. It is also

notable that 4 participants (50%) acquired at least one new isolate resistant to a tested

antimicrobial after a catheter change: 5 of the 23 new acquisitions were resistant organisms

(22%), resulting in an average incidence of new acquisition of resistant organisms of 28%

following catheter changes. It is also notable that 11/51 (22%) study visits during which the

IDSA CAUTI definition was met occurred within 7 days after a catheter change, including 2 of 3

the caregiver-diagnosed CAUTIs. Catheter changes therefore appear to introduce new organisms

and may be associated with development of signs and symptoms of infection.

Three participants with at least 12 weeks of follow-up each received at least one patient-

week of antimicrobial treatment with at least 3 weeks of subsequent follow-up. Treatment

resulted in a combined loss of 8 isolates, with an average loss of 2.7 colonizing isolates per

participant. Similar to catheter changes, 4 of the 8 isolates (50%) were regained within the

subsequent 3 weeks, and 5 new isolates were acquired (average of 1.7 per participant) resulting

in a net increase of 0.3 isolates after antimicrobial treatment. One of the 5 new isolates was

resistant to a tested antimicrobial (20%), resulting in an average incidence of new acquisition of

resistant organisms of 17% following treatment.

**Discussion**

CAUTIs are common in nursing home residents with long-term indwelling catheters and

the leading cause of antimicrobial prescriptions in this population (62). However, it is estimated

that approximately one-third of CAUTIs are misdiagnosed asymptomatic bacteriuria, for which

antimicrobial therapy is not considered to be beneficial (63, 64). Part of the discrepancy is due to

the challenges of diagnosing CAUTI, especially in a patient population that frequently presents

with atypical symptoms. While our sample size was small, our study clearly demonstrates that

nursing home residents with long-term catheters routinely have bacteriuria $>10^5$ CFU/ml

combined with abnormal urinalysis results and numerous possible signs and symptoms of urinary

tract infection. Interestingly, there were no clear differences in the composition of bacteriuria

between weekly asymptomatic cultures and study visits that met the IDSA CAUTI definition.

Further investigation of urine composition using metagenomics and proteomics will be necessary

to determine if development of signs and symptoms of infection correlates with the presence of

other organisms, such as fungi, anaerobic bacteria, and viruses, or to changes in the host immune

response.

Over-testing of urine samples, both by culture and urinalysis, has been demonstrated to

have a predominantly negative impact on patient outcomes including inappropriate antimicrobial

prescription and increased duration of hospitalization (65-71). For instance, detection of pyuria

in preoperative urinalysis was recently demonstrated be associated with prescription of

antimicrobials, even in the absence of a positive urine culture or urinary symptoms (72).

Importantly, pyuria itself was not associated with any negative postoperative outcomes, but the

resulting antimicrobial use increased risk of subsequent *Clostridioides difficile* infection without

improving any other outcomes (72). This issue is further complicated in catheterized individuals,

older adults, and those with neurogenic lower urinary tract dysfunction, for whom pyuria and

positive urine cultures are common, and fever, dysuria, urgency, and pain demonstrate minimal

sensitivity and specificity for differentiating UTI from asymptomatic bacteriuria (27, 67, 73-78).

A recent study identified fever as the primary indication for obtaining a urine culture from

catheterized individuals, even when other urinary symptoms are lacking and there are possible

alternative explanations of fever (79). Abnormal urinalysis is another common indication for

obtaining a urine culture in hospital settings (67), despite lack of other urinary symptoms and

IDSA guidelines to the contrary. Considering the almost ubiquitous bacteriuria and abnormal

urinalysis results observed in this study, coupled with a high prevalence of non-specific signs

and symptoms of possible infection, our data underscore the critical need for discovery of

additional indicators of true infection in this patient population.

Frequent exposure to antimicrobials has been demonstrated to result in a high carriage

rate of antimicrobial resistant organisms in nursing home residents, particularly those with

indwelling devices (8-10). While only 7 of the 19 participants received antimicrobials during the

course of the study, 12 participants (63%) were colonized by at least one bacterium that was

resistant to the tested antimicrobial, and 26% of all urine cultures contained a resistant bacterium,

indicating that the urine of catheterized nursing home residents represents another reservoir of

persistent colonization by resistant organisms. For instance, 9 participants exhibited MRSA

bacteriuria, and colonization persisted for at least 8 weeks in 4 of these participants despite

multiple catheter changes. The same was observed for resistant Gram-negative bacteria.

Regarding persistent colonization, our data indicate that bacteriuria remains remarkably

stable even after numerous catheter changes and that antimicrobial treatment only transiently

reduces colonization. Despite the observation of immediate loss of colonizing organisms in some

instances, the net change in colonization favored an increase following catheter changes and

treatment, including new acquisition of a resistant bacterium. While changing of the catheter

upon initiation of antimicrobial treatment for CAUTI may expand the duration of post-treatment

culture-negative bacteriuria (80), there is no clear improvement of clinical outcomes (81).

Catheter insertions can also have a substantial negative impact due to the risk of creating a false

passage, bladder perforation, external trauma, and hematuria, in addition to potentially inducing

symptomatic CAUTI (70). Our data indicate that routine catheter changes predominantly had a

negative impact in participants with asymptomatic bacteriuria, including new acquisition of

bacteria and new onset signs and symptoms of possible infection. While further studies are

necessary in a larger patient population, these preliminary findings provide support for catheter

care practices of only changing the catheter when necessary and strictly adhering to stewardship

guidelines.

The prevalence of polymicrobial bacteriuria during long-term catheterization has been

widely reported for decades (1, 2, 50). However, polymicrobial clinical urine specimens are

often suspected of harboring periurethral or vaginal microbiota, particularly when they include

Gram-positive organisms (82, 83). This has complicated investigation of the clinical significance

of polymicrobial bacteriuria and assessment of the contribution of these organisms to

pathogenesis. It is therefore notable that prospective assessment of bacteriuria revealed that

*Enterococcus faecalis, Staphylococcus aureus,* and coagulase-negative *Staphylococcus* are

prevalent and persistent constituents of bacteriuria in nursing home residents with long-term

indwelling catheters. The contribution of these species to risk of developing symptomatic

infection and sequelae therefore warrant further investigation, particularly in the context of

polymicrobial colonization. For instance, persistent bacteriuria with these organisms may

facilitate transient bacteremia and hematogenous seeding of other body sites, including

endocarditis (84). In elderly catheterized individuals, ~4% of catheter changes were

demonstrated to result in transient bacteremia, including by coagulase-negative *Staphylococcus*

species (1, 85). Bacteremia due to *S. aureus* has also been observed in ~7% of patients with *S.*

*aureus* bacteriuria, particularly those of advanced age or residing in nursing homes (86).

Furthermore, identification of *S. aureus* bacteriuria ≥48 hours prior to bacteremia was associated

with an increased risk of mortality (86). Further research is necessary to determine if persistent

catheter-associated bacteriuria with Gram-positive organisms increases risk of bacteremia and

hematogenous seeding of other body sites, and if polymicrobial bacteriuria further modifies risk.

Overall, the most frequent and persistent cause of polymicrobial bacteriuria in this study

was *E. faecalis* with *P. mirabilis.* The association of these organisms may have important clinical

implications, as interactions between *P. mirabilis* and *E. faecalis* increase the likelihood of

developing urinary stones and bacteremia in experimental models of CAUTI (17, 60). Ineffective

antimicrobial treatment has also been reported to be more common for polymicrobial UTI and

those involving *E. faecalis* (23). It may therefore be hypothesized that CAUTI sequelae and

mortality may be more common in co-colonized study participants than those who were not co-

colonized. While the present study was not sufficiently powered to address this hypothesis, it is

worth noting that three study participants developed urinary stones, pyelonephritis, or urosepsis

(rows D, G, and J of Figure 1); all three were colonized by *P. mirabilis,* and two exhibited co-

colonization with *E. faecalis.* All three participants were also co-colonized by *Providencia*

*stuartii,* which has similarly been shown to interact with *P. mirabilis* and enhance risk of urinary

stones and bacteremia (17, 87). However, other co-colonized participants did not exhibit

infection or sequelae (such as rows A, C, and E), underscoring that these polymicrobial

interactions are one of many factors that contribute to the risk of developing severe disease.

Further investigation of complex polymicrobial interactions in the catheterized urinary tract are

likely to provide new insight into potential decolonization strategies or therapeutics to reduce the

risk of progressing from asymptomatic bacteriuria to CAUTI and associated sequelae.

The results of this study should be considered in light of several strengths and

weaknesses. Main strengths of the study include 1) prospective longitudinal urine culturing

rather than collection of a single specimen per participant; 2) prospective assessment of infection

signs and symptoms using standardized criteria; 3) weekly study visits conducted by the same

study personnel; 4) weekly urine culturing and antimicrobial susceptibility testing to identify and

characterize all isolates prior to any laboratory adaptation and to monitor dynamics of

colonization; and 5) enrollment at two nursing facilities. Limitations of the study include the

limited sample size, low diversity of study participants, limited duration of follow-up for some

study participants, and inability to collect urine samples from all participants at all study visits.

While our study is exploratory in nature and these limitations preclude more sophisticated

analysis of the relationship between specific organisms and clinical presentation, this study still

represents a significant advance in our understanding of the dynamics and epidemiology of

bacteriuria in catheterized nursing home residents. Further investigations of this nature may

uncover combinations of organisms that predict likelihood of developing infection and sequelae,

or patterns of clinical signs and symptoms associated with colonization by specific organisms. If

so, this information could help in refining existing tools and determining which course of action

should be taken for a given patient, therefore guiding appropriate antimicrobial treatment and

possibly reducing acquisition of antimicrobial resistance.

**Methods**

**Ethics statement.** This study was approved by the University at Buffalo Institutional Review Board (STUDY00002526) and complied with the provisions of the Declaration of Helsinki, Good Clinical Practice guidelines, and local laws and regulations. All participants (or approved decision makers) provided written informed consent prior to initiation of investigation, and all participants also assented to being in the study.

**Study design.** A prospective observational cohort study of asymptomatic catheter-associated bacteriuria was conducted at two nursing homes located in Buffalo, New York between July 2019 and March 2020. Study visits occurred at enrollment and weekly thereafter for up to 7 months. Each study visit entailed chart review by trained research staff as well as a brief assessment of possible signs and symptoms of infection and collection of a urine specimen by one of three licensed practicing nurses (LPNs) from the Visiting Nurse Association of Western New York. Participants were withdrawn from the study upon indication that they no longer wanted to participate, removal of the indwelling catheter without replacement, transfer to a non-participating facility, or death. All study data and records were managed using REDCap (Research Electronic Data Capture) tools (88, 89), hosted through the University at Buffalo Clinical and Translational Science Institute.

**Inclusion criteria.** Nursing home residents at either of the two participating facilities were eligible for inclusion if they had an indwelling urinary catheter (Foley or suprapubic) for at least 12 months, were at least 21 years of age, were capable of assenting to participation, and

informed consent could be obtained from the resident or approved decision maker. Residents

receiving end-of-life care were excluded from the study.

**Data collection from chart review.** Information pertaining to participant demographics, age,

weight, gender, comorbidities, functional status, indication for catheterization, duration of

indwelling catheter use, history of urinary tract infection, and history of antimicrobial use were

obtained from participant medical records by trained research staff on the baseline visit. Chart

reviews were also conducted at each weekly study visit to obtain information pertaining

suspected infections, hospitalizations, urine culture results, urinalysis results, and antimicrobial

prescriptions. Potential signs and symptoms of CAUTI that were recorded include fever (defined

as having a single temperature >100°F or repeated temperatures >99°F or >2°F above baseline),

new onset suprapubic or costovertebral pain or tenderness, new onset hypotension, chills or

rigors, and acute mental status change (defined as a fluctuation in behavior, inattention,

disorganized thinking, or an altered level of consciousness compared to baseline) (24, 25).

If a study participant was temporarily transferred to a hospital, medical records from the hospital

stay were utilized to obtain information pertaining to suspected infections.

**Assessment of possible signs and symptoms of infection.** At each study visit, an LPN collected

vital signs (tympanic temperature and blood pressure) and assessed costovertebral and

suprapubic pain or tenderness. The LPN and a study team member also conducted a Delirium

Triage Screen (DTS) (90) at the start of each visit, and a Brief Confusion Assessment Method

(bCAM) (90) assessment at the end of each visit to identify altered mental status (defined as

fluctuating altered mental status, including altered level of consciousness, inattention, and

disorganized thinking). The LPN and study team member also administered an oral questionnaire

at each study visit to determine if the participant had experienced rigors or chills, nausea, lack of

appetite, or fatigue since the previous visit.

**Urine collection.** Urine specimens were collected from the port of the indwelling catheter by an

LPN using aseptic technique. Briefly, the catheter tubing was clamped ~12 inches below the

latex rubber port and urine was allowed to collect for approximately 30 minutes. The catheter

port was then swabbed with an alcohol wipe and allowed to dry for ~30 seconds. The needle of a

sterile syringe was then inserted into the port, and urine was withdrawn and transferred into a

sterile specimen jar. Urine specimens were placed in an insulated cooler with ice packs and

stored therein for no more than 4 hours prior to culturing.

**Processing of urine specimens.** Each urine specimen was utilized for isolation and

identification of colonizing bacterial species, urinalysis via 10-parameter urine reagent test strip

(LW Scientific, Lawrenceville, Georgia), and generation of urine glycerol stock for long-term

storage and re-isolation if needed. Remaining urine was also frozen at -80°C for future analyses.

For detection of Gram-positive and Gram-negative bacteria, a 1 µl calibrated inoculating

loop (Laboratory Products Sales, Inc, Rochester, NY) was used for semi-quantitative streak-

plating on four types of agar from Hardy Diagnostics (Santa Maria, California):  HardyCHROM

UTI, Columbia CNA, Bile Esculin (BEA), and MacConkey. All distinct colonies that could be

differentiated by morphology, hemolysis, or color were isolated for further analysis.

Gram-positive bacteria from CNA and BEA plates were tested for catalase using 30%

hydrogen peroxide and for PYR activity (Hardy Diagnostics). Isolates that were PYR-positive

and catalase-negative were suspected to be *Enterococcus* species, and identified to the species

level using previously-described primer sets (91). Isolates that were PYR-negative and catalase-

positive were suspected to be *Staphylococcus* species, and subjected to Sure-Vue™ SELECT

(Fisher Healthcare) to distinguish *Staphylococcus aureus* from coagulase-negative

*Staphylococcus* species. PYR-negative and catalase-negative were suspected to be *Streptococcus*

species, and were subjected to a Streptex™ Latex Agglutination Test (Thermo Scientific).

Suspected *Streptococcus* isolates that did not have a positive Streptex reaction were designated

"miscellaneous PYR-negative catalase-negative Gram-positive isolates".

Gram-negative bacteria from MacConkey plates were identified to the species level

whenever possible using API-20E test strips (BioMérieux, Marcy-l'Étoile, France). Isolates

identified as *Pseudomonas aeruginosa* via API-20E were confirmed using previously-described

primer sets (92). *Proteus mirabilis* and *Proteus vulgaris* isolates were confirmed by swarming

motility on blood agar plates (Hardy Diagnostics).

Isolates of a given organism from consecutive urines specimens from the same

participant were assumed to be the same strain if they were the same genus and species, the API-

20E biotype number varied by no more than two digits (for Gram-negative isolates), and if

colony morphology and antimicrobial susceptibility profiles were consistent week-to-week (see

below). If a strain was absent in one urine specimen but had been present in the preceding and

following specimens from that participant, re-isolation was attempted from the urine glycerol

stock. If the strain still could not be detected, it was assumed to be absent from that urine

specimen.

**Antimicrobial susceptibility testing.** Antimicrobial susceptibility was assessed by zone of

growth inhibition on Mueller-Hinton agar (Hardy Diagnostics). Zone diameters indicative of

susceptibility were determined using the Clinical and Laboratory Standards Institute (CLSI)

breakpoints listed in the M100 30th edition (93, 94). *Enterococcus* isolates were tested for

vancomycin sensitivity using Etest strips (Hardy Diagnostics), and a minimum inhibitory

concentration of ≤4 ug/ml was considered susceptible. *S. aureus* isolates were tested for

methicillin susceptibility using cefoxitin (Hardy Diagnostics), and susceptibility was defined as a

zone diameter of ≥18 mm. Gram-negative isolates were tested for susceptibility to ciprofloxacin

(Hardy Diagnostics) (≥21 mm zone diameter), ceftazidime (Hardy Diagnostics) (≥18 mm zone

diameter), ceftazidime with clavulanate (Hardy Diagnostics) (≥20 mm zone diameter), and

imipenem (Hardy Diagnostics) (≥15 mm zone diameter).

**Statistical Analysis.** Data were analyzed by a combination of chi square tests and logistic

regression, as indicated, using StataIC 15.1 (StatCorp, College Station, Texas). All logistic

regressions were adjusted for participant-level clustering to account for multiple samples per

participant.

## Acknowledgments

We would like to thank members of the Department of Microbiology & Immunology, the Division of Infectious Diseases, and Witebsky Center for Microbial Pathogenesis and Immunology for helpful comments and critiques. We would also like to thank the nursing home administrators and staff and the Visiting Nurse Association of Western New York. This work was supported by the National Institutes of Health via the National Institute of Diabetes Digestive and Kidney Diseases [R00 DK105205 and R01 DK123158 to C.E.A.] and the National Center for Advancing Translational Sciences (UL1 TR001412 to the University at Buffalo). The sponsors were not involved in the study design, methods, subject recruitment, data collections, analysis, or preparation of the paper. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funders.

## Author Contributions

Conceptualization, C.E.A.; Methodology, C.E.A.; Validation, C.E.A. and A.L.B; Formal Analysis, C.E.A., A.L.B., and M.S.H.; Investigation, C.E.A., A.L.B., and M.S.H.; Resources, C.E.A.; Data Curation, C.E.A., A.L.B., and M.S.H.; Writing – Original Draft Preparation, C.E.A.; Writing – Review & Editing, all authors.; Visualization, C.E.A.; Supervision, C.E.A.; Project Administration, C.E.A.; Funding Acquisition, C.E.A..

## Competing Interests

The authors have no financial or non-financial competing interests to declare.

**References**

1. Hooton TM, Bradley SF, Cardenas DD, Colgan R, Geerlings SE, Rice JC, et al. Diagnosis, Prevention, and Treatment of Catheter-Associated Urinary Tract Infection in Adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. *Clinical Infectious Diseases.* 2010;50(5):625-63.

2. Nicolle LE. Urinary Catheter-Associated Infections. *Infectious Disease Clinics of North America.* 2012;26(1):13-27.

3. Dudeck MA, Edwards JR, Allen-Bridson K, Gross C, Malpiedi PJ, Peterson KD, et al. National Healthcare Safety Network report, data summary for 2013, Device-associated Module. *Am J Infect Control.* 2015;43(3):206-21.

4. Rogers MAM, Mody L, Kaufman SR, Fries BE, McMahon LF, and Saint S. Use of Urinary Collection Devices in Skilled Nursing Facilities in Five States. *Journal of the American Geriatrics Society.* 2008;56(5):854-61.

5. Tsan L, Langberg R, Davis C, Phillips Y, Pierce J, Hojlo C, et al. Nursing home-associated infections in Department of Veterans Affairs community living centers. *American Journal of Infection Control.* 2010;38(6):461-6.

6. Kunin CM, Douthitt S, Dancing J, Anderson J, and Moeschberger M. The Association between the Use of Urinary Catheters and Morbidity and Mortality among Elderly Patients in Nursing-Homes. *American journal of epidemiology.* 1992;135(3):291-301.

7. Crnich CJ, and Drinka P. Medical device-associated infections in the long-term care setting. *Infect Dis Clin North Am.* 2012;26(1):143-64.

8. Nicolle LE. Catheter associated urinary tract infections. *Antimicrob Resist In.* 2014;3.

9.  Mody L, Krein SL, Saint S, and et al. A targeted infection prevention intervention in

nursing home residents with indwelling devices: A randomized clinical trial. *JAMA*

*Internal Medicine.* 2015;175(5):714-23.

10.  Wang L, Lansing B, Symons K, Flannery EL, Fisch J, Cherian K, et al. Infection rate and

colonization with antibiotic-resistant organisms in skilled nursing facility residents with

indwelling devices. *Eur J Clin Microbiol Infect Dis.* 2012;31(8):1797-804.

11.  Averch TD, Stoffel J, Goldman HB, Griebling TL, Lerner L, Newman DK, et al. AUA

White Paper on Catheter Associated Urinary Tract Infections: Definitions and

Significance in the Urological Patient. *Urology Practice.* 2015;2(6):321-8.

12.  Garcia MM, Gulati S, Liepmann D, Stackhouse GB, Greene K, and Stoller ML.

Traditional Foley Drainage Systems—Do They Drain the Bladder? *The Journal of*

*Urology.* 2007;177(1):203-7.

13.  Willette PA, and Coffield SK. Current Trends in the Management of Difficult Urinary

Catheterizations. *Western Journal of Emergency Medicine.* 2012;13(6).

14.  Armbruster C, Mobley H, and Pearson M. Pathogenesis of *Proteus mirabilis* Infection.

*EcoSal Plus.* 2018.

15.  Hofseth LJ, Dunn BP, and Rosin MP. Micronucleus frequencies in urothelial cells of

catheterized patients with chronic bladder inflammation. *Mutation*

*Research/Fundamental and Molecular Mechanisms of Mutagenesis.* 1996;352(1–2):65-

72.

16.  Anderson RU. Response of bladder and urethral mucosa to catheterization. *JAMA.*

1979;242(5):451-3.

17.    Armbruster CE, Smith SN, Johnson AO, DeOrnellas V, Eaton KA, Yep A, et al. The

Pathogenic Potential of *Proteus mirabilis* is Enhanced by Other Uropathogens During

Polymicrobial Urinary Tract Infection. *Infection and Immunity.* 2017;85(2):e00808-16.

18.    Nicolle LE. Catheter-related urinary tract infection: practical management in the elderly.

*Drugs Aging.* 2014;31(1):1-10.

19.    Daniels KR, Lee GC, and Frei CR. Trends in catheter-associated urinary tract infections

among a national cohort of hospitalized adults, 2001-2010. *American Journal of Infection*

*Control.* 2014;42(1):17-22.

20.    Warren JW, Damron D, Tenney JH, Hoopes JM, Deforge B, and Muncie HL, Jr. Fever,

bacteremia, and death as complications of bacteriuria in women with long-term urethral

catheters. *J Infect Dis.* 1987;155(6):1151-8.

21.    Bootsma AM, Buurman BM, Geerlings SE, and de Rooij SE. Urinary incontinence and

indwelling urinary catheters in acutely admitted elderly patients: relationship with

mortality, institutionalization, and functional decline. *J Am Med Dir Assoc.*

2013;14(2):147 e7-12.

22.    Chant C, Smith OM, Marshall JC, and Friedrich JO. Relationship of catheter-associated

urinary tract infection to mortality and length of stay in critically ill patients: a systematic

review and meta-analysis of observational studies. *Crit Care Med.* 2011;39(5):1167-73.

23.    Esparcia A, Artero A, Eiros JM, Balaguer M, Madrazo M, Alberola J, et al. Influence of

inadequate antimicrobial therapy on prognosis in elderly patients with severe urinary tract

infections. *Eur J Intern Med.* 2014;25(6):523-7.

24.    Loeb M, Bentley DW, Bradley S, Crossley K, Garibaldi R, Gantz N, et al. Development

of minimum criteria for the initiation of antibiotics in residents of long-term-care

facilities: results of a consensus conference. *Infect Control Hosp Epidemiol.*

2001;22(2):120-4.

25.   Stone ND, Ashraf MS, Calder J, Crnich CJ, Crossley K, Drinka PJ, et al. Surveillance

definitions of infections in long-term care facilities: revisiting the McGeer criteria. *Infect*

*Control Hosp Epidemiol.* 2012;33(10):965-77.

26.   Fekete T. Catheter-associated urinary tract infection in adults.

https://www.uptodate.com/contents/catheter-associated-urinary-tract-infection-in-adults.

Accessed September 27, 2020, 2020.

27.   Nicolle LE, Gupta K, Bradley SF, Colgan R, DeMuri GP, Drekonja D, et al. Clinical

Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by

the Infectious Diseases Society of Americaa. *Clinical Infectious Diseases.*

2019;68(10):1611-5.

28.   (NHSN) NHSN. Atlanta, GA: Division of Healthcare Quality Promotion, National Center

for Emergine and Zoonotic Infectious Diseases; 2020.

29.   High K. Evaluation of infection in the older adult.

http://www.uptodate.com/contents/evaluation-of-infection-in-the-older-

adult?source=see_link.  Accessed 04/10/2016, 2016.

30.   Mouton CP, Bazaldua OV, Pierce B, and Espino DV. Common infections in older adults.

*Am Fam Physician.* 2001;63(2):257-68.

31.   Armbruster CE, Prenovost K, Mobley HLT, and Mody L. How Often Do Clinically

Diagnosed Catheter-Associated Urinary Tract Infections in Nursing Home Residents

Meet Standardized Criteria? *J Am Geriatr Soc.* 2017;65(2):395-401.

32.　Tambyah PA, and Maki DG. Catheter-associated urinary tract infection is rarely

symptomatic: a prospective study of 1,497 catheterized patients. *Arch Intern Med.*

2000;160(5):678-82.

33.　Cope M, Cevallos ME, Cadle RM, Darouiche RO, Musher DM, and Trautner BW.

Inappropriate treatment of catheter-associated asymptomatic bacteriuria in a tertiary care

hospital. *Clin Infect Dis.* 2009;48(9):1182-8.

34.　Kizilbash QF, Petersen NJ, Chen GJ, Naik AD, and Trautner BW. Bacteremia and

mortality with urinary catheter-associated bacteriuria. *Infect Control Hosp Epidemiol.*

2013;34(11):1153-9.

35.　Shortliffe LMD, and McCue JD. Urinary tract infection at the age extremes: pediatrics

and geriatrics. *The American Journal of Medicine.* 2002;113(1, Supplement 1):55-66.

36.　Mayne S, Sundvall P-D, and Gunnarsson R. Confusion Strongly Associated with

Antibiotic Prescribing Due to Suspected Urinary Tract Infections in Nursing Homes.

*Journal of the American Geriatrics Society.* 2018;66(2):274-81.

37.　Nicolle LE. Asymptomatic Bacteriuria and Bacterial Interference. *Microbiology*

*spectrum.* 2015;3(5).

38.　Nace DA, Drinka PJ, and Crnich CJ. Clinical uncertainties in the approach to long term

care residents with possible urinary tract infection. *J Am Med Dir Assoc.* 2014;15(2):133-

9.

39.　Agata ED, Loeb MB, and Mitchell SL. Challenges in Assessing Nursing Home Residents

with Advanced Dementia for Suspected Urinary Tract Infections. *Journal of the*

*American Geriatrics Society.* 2013;61(1):62-6.

40.    Juthani-Mehta M, Tinetti M, Perrelli E, Towle V, Van Ness PH, and Quagliarello V.

639            Interobserver variability in the assessment of clinical criteria for suspected urinary tract

640            infection in nursing home residents. *Infection control and hospital epidemiology.*

641            2008;29(5):446-9.

642    41.    Juthani-Mehta M, Quagliarello V, Perrelli E, Towle V, Van Ness PH, and Tinetti M.

643            Clinical Features to Identify Urinary Tract Infection in Nursing Home Residents: A

644            Cohort Study. *Journal of the American Geriatrics Society.* 2009;57(6):963-70.

645    42.    Dedeic-Ljubovic A, and Hukic M. Catheter-related urinary tract infection in patients

646            suffering from spinal cord injuries. *Bosn J Basic Med Sci.* 2009;9(1):2-9.

647    43.    Ronald A. The etiology of urinary tract infection: traditional and emerging pathogens.

648            *Dis Mon.* 2003;49(2):71-82.

649    44.    Siegman-Igra Y, Kulka T, Schwartz D, and Konforti N. Polymicrobial and

650            monomicrobial bacteraemic urinary tract infection. *Journal of Hospital Infection.*

651            1994;28(1):49-56.

652    45.    Kunin CM. Blockage of urinary catheters: Role of microorganisms and constituents of

653            the urine on formation of encrustations. *Journal of Clinical Epidemiology.*

654            1989;42(9):835-42.

655    46.    Rahav G, Pinco E, Silbaq F, and Bercovier H. Molecular epidemiology of catheter-

656            associated bacteriuria in nursing home patients. *J Clin Microbiol.* 1994;32(4):1031-4.

657    47.    Mobley HLT, and Warren JW. Urease-Positive Bacteriuria and Obstruction of Long-

658            Term Urinary Catheters. *J Clin Microbiol.* 1987;25(11):2216-7.

659    48.    Breitenbucher RB. Bacterial changes in the urine samples of patients with long-term

660            indwelling catheters. *Arch Intern Med.* 1984;144(8):1585-8.

49.   Warren JW, Tenney JH, Hoopes JM, Muncie HL, and Anthony WC. A Prospective

Microbiologic Study of Bacteriuria in Patients with Chronic Indwelling Urethral

Catheters. *Journal of Infectious Diseases.* 1982;146(6):719-23.

50.   Nicolle LE. Catheter-Related Urinary Tract Infection. *Drugs & Aging.* 2005;22(8):627-

39.

51.   Armbruster CE, and Mobley HLT. Merging mythology and morphology: the multifaceted

lifestyle of *Proteus mirabilis*. *Nat Rev Micro.* 2012;10(11):743-54.

52.   Jonsson K, Claesson BE, and Hedelin H. Urine cultures from indwelling bladder

catheters in nursing home patients: a point prevalence study in a Swedish county. *Scand J*

*Urol Nephrol.* 2011;45(4):265-9.

53.   Fourcade C, Canini L, Lavigne JP, and Sotto A. A comparison of monomicrobial versus

polymicrobial Enterococcus faecalis bacteriuria in a French University Hospital. *Eur J*

*Clin Microbiol Infect Dis.* 2015;34(8):1667-73.

54.   Schaeffer AJ. Catheter-associated bacteriuria. *Urol Clin North Am.* 1986;13(4):735-47.

55.   Lawton MP, and Brody EM. Assessment of older people: self-maintaining and

instrumental activities of daily living. *Gerontologist.* 1969;9(3):179-86.

56.   Murray JL, Connell JL, Stacy A, Turner KH, and Whiteley M. Mechanisms of synergy in

polymicrobial infections. *Journal of Microbiology.* 2014;52(3):188-99.

57.   Nair N, Biswas R, Götz F, and Biswas L. Impact of Staphylococcus aureus on

Pathogenesis in Polymicrobial Infections. *Infection and Immunity.* 2014;82(6):2162-9.

58.   Short FL, Murdoch SL, and Ryan RP. Polybacterial human disease: the ills of social

networking. *Trends in Microbiology.* 2014;22(9):508-16.

59.   Tay WH, Chong KK, and Kline KA. Polymicrobial-Host Interactions during Infection. *J*

*Mol Biol.* 2016.

60.   Learman BS, Brauer AL, Eaton KA, and Armbruster CE. A Rare Opportunist,

Morganella morganii, Decreases Severity of Polymicrobial Catheter-Associated Urinary

Tract Infection. *Infection and Immunity.* 2019;88(1):e00691-19.

61.   Hajishengallis G, and Lamont RJ. Dancing with the Stars: How Choreographed Bacterial

Interactions Dictate Nososymbiocity and Give Rise to Keystone Pathogens, Accessory

Pathogens, and Pathobionts. *Trends in Microbiology.* 2016;24(6):477-89.

62.   Loeb M, Brazil K, Lohfeld L, McGeer A, Simor A, Stevenson K, et al. Optimizing

antibiotics in residents of nursing homes: protocol of a randomized trial. *BMC health*

*services research.* 2002;2(1):17.

63.   Loeb M, Simor AE, Landry L, Walter S, McArthur M, Duffy J, et al. Antibiotic use in

Ontario facilities that provide chronic care. *Journal of general internal medicine.*

2001;16(6):376-83.

64.   Nicolle LE, Bradley S, Colgan R, Rice JC, Schaeffer A, Hooton TM, et al. Infectious

Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic

bacteriuria in adults. *Clin Infect Dis.* 2005;40(5):643-54.

65.   Smith M-A, Puckrin R, Lam PW, Lamb MJ, Simor AE, and Leis JA. Association of

Increased Colony-Count Threshold for Urinary Pathogens in Hospitalized Patients With

Antimicrobial Treatment. *JAMA Internal Medicine.* 2019;179(7):990-2.

66.   Leis JA, Rebick GW, Daneman N, Gold WL, Poutanen SM, Lo P, et al. Reducing

Antimicrobial Therapy for Asymptomatic Bacteriuria Among Noncatheterized Inpatients:

A Proof-of-Concept Study. *Clinical Infectious Diseases.* 2014;58(7):980-3.

67. Petty LA, Vaughn VM, Flanders SA, Malani AN, Conlon A, Kaye KS, et al. Risk Factors

and Outcomes Associated With Treatment of Asymptomatic Bacteriuria in Hospitalized

Patients. *JAMA Internal Medicine.* 2019;179(11):1519-27.

68. Spivak ES, Burk M, Zhang R, Jones MM, Neuhauser MM, Goetz MB, et al. Management

of Bacteriuria in Veterans Affairs Hospitals. *Clin Infect Dis.* 2017;65(6):910-7.

69. Hartley S, Valley S, Kuhn L, Washer LL, Gandhi T, Meddings J, et al. Overtreatment of

Asymptomatic Bacteriuria: Identifying Targets for Improvement. *Infection Control &*

*Hospital Epidemiology.* 2015;36(4):470-3.

70. Leuck A-M, Wright D, Ellingson L, Kraemer L, Kuskowski MA, and Johnson JR.

Complications of Foley Catheters—Is Infection the Greatest Risk? *Journal of*

*Urology.* 2012;187(5):1662-6.

71. Das R, Towle V, Van Ness PH, and Juthani-Mehta M. Adverse outcomes in nursing

home residents with increased episodes of observed bacteriuria. *Infect Control Hosp*

*Epidemiol.* 2011;32(1):84-6.

72. Gupta K, O'Brien W, Gallegos-Salazar J, Strymish J, and Branch-Elliman W. How

Testing Drives Treatment in Asymptomatic Patients: Level of Pyuria Directly Predicts

Probability of Antimicrobial Prescribing. *Clin Infect Dis.* 2020;71(3):614-21.

73. Tambyah PA, and Maki DG. The Relationship Between Pyuria and Infection in Patients

With Indwelling Urinary Catheters: A Prospective Study of 761 Patients. *Archives of*

*Internal Medicine.* 2000;160(5):673-7.

74. Tambyah PA, and Maki DG. Catheter-Associated Urinary Tract Infection Is Rarely

Symptomatic: A Prospective Study of 1497 Catheterized Patients. *Archives of Internal*

*Medicine.* 2000;160(5):678-82.

75.    Orr PH, Nicolle LE, Duckworth H, Brunka J, Kennedy J, Murray D, et al. Febrile urinary

730           infection in the institutionalized elderly. *The American Journal of Medicine.*

731           1996;100(1):71-7.

732    76.    Kunin CM, Chin QF, and Chambers S. Morbidity and Mortality Associated with

733           Indwelling Urinary Catheters in Elderly Patients in a Nursing Home—Confounding Due

734           to the Presence of Associated Diseases. *Journal of the American Geriatrics Society.*

735           1987;35(11):1001-6.

736    77.    Mody L, and Juthani-Mehta M. Urinary tract infections in older women: a clinical

737           review. *JAMA.* 2014;311(8):844-54.

738    78.    Tornic J, Wöllner J, Leitner L, Mehnert U, Bachmann LM, and Kessler TM. The

739           Challenge of Asymptomatic Bacteriuria and Symptomatic Urinary Tract Infections in

740           Patients with Neurogenic Lower Urinary Tract Dysfunction. *Journal of Urology.*

741           2020;203(3):579-84.

742    79.    Tedja R, Wentink J, O'Horo JC, Thompson R, and Sampathkumar P. Catheter-

743           Associated Urinary Tract Infections in Intensive Care Unit Patients. *Infection Control &*

744           *Hospital Epidemiology.* 2015;36(11):1330-4.

745    80.    RAZ R, SCHILLER D, and NICOLLE LE. CHRONIC INDWELLING CATHETER

746           REPLACEMENT BEFORE ANTIMICROBIAL THERAPY FOR SYMPTOMATIC

747           URINARY TRACT INFECTION. *Journal of Urology.* 2000;164(4):1254-8.

748    81.    Babich T, Zusman O, Elbaz M, Ben-Zvi H, Paul M, Leibovici L, et al. Replacement of

749           Urinary Catheter for Urinary Tract Infections: A Prospective Observational Study.

750           *Journal of the American Geriatrics Society.* 2018;66(9):1779-84.

751    82.    Kline KA, and Lewis AL. Gram-Positive Uropathogens, Polymicrobial Urinary Tract

752           Infection, and the Emerging Microbiota of the Urinary Tract. *Microbiology spectrum.*

753           2016;4(2).

754    83.    Hooton TM. Clinical practice. Uncomplicated urinary tract infection. *The New England*

755           *journal of medicine.* 2012;366(11):1028-37.

756    84.    Chenoweth CE, Gould CV, and Saint S. Diagnosis, management, and prevention of

757           catheter-associated urinary tract infections. *Infect Dis Clin North Am.* 2014;28(1):105-19.

758    85.    Bregenzer T, Frei R, Widmer AF, Seiler W, Probst W, Mattarelli G, et al. Low Risk of

759           Bacteremia During Catheter Replacement in Patients With Long-term Urinary Catheters.

760           *Archives of Internal Medicine.* 1997;157(5):521-5.

761    86.    Stokes W, Parkins MD, Parfitt ECT, Ruiz JC, Mugford G, and Gregson DB. Incidence

762           and Outcomes of Staphylococcus aureus Bacteriuria: A Population-based Study. *Clinical*

763           *Infectious Diseases.* 2018;69(6):963-9.

764    87.    Armbruster CE, Smith SN, Yep A, and Mobley HLT. Increased Incidence of Urolithiasis

765           and Bacteremia During *Proteus mirabilis* and *Providencia stuartii* Coinfection Due to

766           Synergistic Induction of Urease Activity. *Journal of Infectious Diseases.*

767           2014;209(10):1524-32.

768    88.    Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap

769           consortium: Building an international community of software platform partners. *J*

770           *Biomed Inform.* 2019;95:103208.

771    89.    Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, and Conde JG. Research electronic

772           data capture (REDCap)--a metadata-driven methodology and workflow process for

providing translational research informatics support. *J Biomed Inform.* 2009;42(2):377-81.

90.  Han JH, Wilson A, Vasilevskis EE, Shintani A, Schnelle JF, Dittus RS, et al. Diagnosing delirium in older emergency department patients: validity and reliability of the delirium triage screen and the brief confusion assessment method. *Ann Emerg Med.* 2013;62(5):457-65.

91.  Layton BA, Walters SP, Lam LH, and Boehm AB. Enterococcus species distribution among human and animal hosts using multiplex PCR. *Journal of Applied Microbiology.* 2010;109(2):539-47.

92.  Spilker T, Coenye T, Vandamme P, and LiPuma JJ. PCR-Based Assay for Differentiation of <em>Pseudomonas aeruginosa</em> from Other <em>Pseudomonas</em> Species Recovered from Cystic Fibrosis Patients. *J Clin Microbiol.* 2004;42(5):2074-9.

93.  Weinstein MP, Lewis JS, Bobenchik AM, Campeau S, Cullen SK, Galas MF, et al. M100: Performance Standards for Antimicrobial Susceptibility Testing. *Clinical and Laboratory Standards Institute.* 2020.

94.  Humphries RM, Abbott AN, and Hindler JA. Understanding and Addressing CLSI Breakpoint Revisions: a Primer for Clinical Laboratories. *J Clin Microbiol.* 2019;57(6).

792    **Table 1.** Characteristics of study participants.

|  | Total (n=19) |
|---|---|
| Age, mean (SD;range), years | 65 (15;43-91) |
| Weight, mean (SD;range), pounds | 182 (26;117-220) |
| PSMS, mean (SD;range) | 22 (4;13-27) |
| Duration of catheter use (years), mean (SD;range)[a] | 6.5 (4.7; 1-17) |
| Duration of follow-up (weeks), mean (SD; range) | 13.0 (11.0; 1-30) |
| Number of catheter changes, mean (SD;range) | 2.6 (3.6; 0-12) |
| Gender |  |
|    Male | 15 (79) |
|    Female | 4 (21) |
| Race |  |
|    White | 15 (79) |
|    Black or African American | 4 (21) |
| Catheter type |  |
|    Foley | 6 (32) |
|    Suprapubic | 13 (68) |
| Indication for catheter use |  |
|    Urinary retention or outlet obstruction | 19 (100) |
| Facility |  |
|    A | 8 (42) |
|    B | 11 (58) |
| Underlying conditions |  |
|    Neurogenic bladder | 14 (74) |
|    Hemiplegia | 8 (42) |
|    Diabetes | 6 (32) |
|    Renal disease | 6 (32) |
|    Multiple sclerosis | 5 (26) |
|    Chronic heart failure | 5 (26) |
|    Dementia | 4 (21) |

793    Data are No. (%) of residents, unless otherwise indicated.  SD, standard deviation; PSMS,
794    physical self-maintenance score.

795    [a]If date of first catheter placement could not be determined, date of admission to facility with
796    catheter in pace was utilized.

797    **Table 2.** Clinical Presentation of Catheter-Associated Bacteriuria

| | Baseline Occurrence | [a]Point prevalence | Patient weeks | [b]Weekly prevalence | New episodes | [c]Incidence | Number of one-week episodes | [d]Proportion of one-week episodes |
|---|---|---|---|---|---|---|---|---|
| $\geq 10^5$ CFU/ml | 19 | 1.00 | 231 | 0.99 | 1 | 0.00 | 0 | 0.00 |
| Hypotension | 4 | 0.21 | 55 | 0.21 | 21 | 0.08 | 15 | 0.71 |
| Fatigue | 4 | 0.21 | 48 | 0.18 | 13 | 0.05 | 8 | 0.62 |
| [e]Altered mental status | 5 | 0.26 | 46 | 0.18 | 19 | 0.07 | 13 | 0.68 |
| Lack of appetite | 3 | 0.16 | 43 | 0.17 | 17 | 0.07 | 12 | 0.71 |
| [f]Pain | 3 | 0.16 | 38 | 0.15 | 9 | 0.03 | 5 | 0.56 |
| Nausea | 2 | 0.11 | 31 | 0.12 | 11 | 0.04 | 5 | 0.45 |
| [g]Fever | 0 | 0.00 | 11 | 0.04 | 11 | 0.04 | 11 | 1.00 |
| Chills | 0 | 0.00 | 10 | 0.04 | 7 | 0.03 | 4 | 0.57 |
| Leukocytosis | 0 | 0.00 | 2 | 0.01 | 2 | 0.01 | 2 | 1.00 |

[a] Number of baseline visits with symptom divided by the total number of baseline visits

[b] Number of patient-weeks symptom was detected divided by total number of patient-weeks

[c] Number of new instances of symptom divided by total number of patient-weeks

[d] Number of episodes lasting only one week divided by the number of new episodes (excluding
the first and last study visits)

[e] Altered mental status was assessed by bCAM and DTS (see methods)

[f] Pain refers to costovertebral or suprapubic pain or tenderness

[g] Fever was defined as having a temperature >99°F

**Table 3.** Urinalysis of Catheter-Associated Bacteriuria

| | Baseline Occurrence | [a]Point prevalence | Patient weeks | [b]Weekly prevalence | New episodes | [c]Incidence | Number of one-week episodes | [d]Proportion of one-week episodes |
|---|---|---|---|---|---|---|---|---|
| Leukocytes | 17 | 0.89 | 213 | 0.91 | 8 | 0.03 | 0 | 0 |
| Protein | 10 | 0.53 | 131 | 0.56 | 30 | 0.13 | 13 | 0.43 |
| Nitrite | 10 | 0.53 | 124 | 0.53 | 36 | 0.15 | 16 | 0.44 |
| Blood | 8 | 0.42 | 75 | 0.32 | 14 | 0.06 | 12 | 0.86 |
| pH ≥7.25 | 4 | 0.21 | 105 | 0.45 | 29 | 0.12 | 4 | 0.14 |
| Ketone | 0 | 0.00 | 14 | 0.06 | 9 | 0.04 | 6 | 0.67 |
| Urobilinogen | 0 | 0.00 | 2 | 0.01 | 2 | 0.01 | 2 | 1.00 |
| Bilirubin | 0 | 0.00 | 2 | 0.01 | 2 | 0.01 | 2 | 1.00 |
| Glucose | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |

[a] Number of baseline urine urinalysis finding divided by the total number of baseline urines

[b] Number of patient-weeks urinalysis finding was detected divided by total number of patient-
weeks

[c] Number of new instances of urinalysis finding divided by total number of patient-weeks

[d] Number of episodes lasting only one week divided by the number of new episodes (excluding
the first and last study visits)

**Table 4.** Epidemiology of Catheter-Associated Bacteriuria

| | Baseline Occurrence | [a]Point prevalence | Patient weeks | [b]Weekly prevalence | New episodes | [c]Incidence | Number of one-week episodes | [d]Proportion of one-week episodes | Number of resistant isolates | [e]Resistance prevalence |
|---|---|---|---|---|---|---|---|---|---|---|
| *Enterococcus faecalis* | 14 | 0.74 | 163 | 0.63 | 4 | 0.02 | 0 | 0.00 | 0 | 0.00 |
| *Providencia stuartii* | 8 | 0.42 | 111 | 0.43 | 6 | 0.02 | 0 | 0.00 | 49 | 0.44 |
| *Proteus mirabilis* | 6 | 0.32 | 118 | 0.45 | 5 | 0.02 | 0 | 0.00 | 81 | 0.69 |
| *Escherichia coli* | 7 | 0.37 | 89 | 0.34 | 3 | 0.01 | 0 | 0.00 | 26 | 0.29 |
| Misc | 6 | 0.32 | 96 | 0.37 | 12 | 0.05 | 4 | 0.33 | ND | ND |
| *Staphylococcus aureus* | 10 | 0.53 | 160 | 0.62 | 10 | 0.04 | 5 | 0.50 | 81 | 0.48 |
| MRSA | 5 | 0.26 | 81 | 0.31 | 12 | 0.05 | 5 | 0.42 | 81 | 1.00 |
| MSSA | 5 | 0.26 | 87 | 0.33 | 8 | 0.03 | 2 | 0.25 | 0 | 0.00 |
| *Morganella morganii* | 2 | 0.11 | 64 | 0.25 | 14 | 0.05 | 4 | 0.29 | 24 | 0.37 |
| *Pseudomonas aeruginosa* | 4 | 0.21 | 66 | 0.25 | 18 | 0.07 | 6 | 0.33 | 19 | 0.29 |
| CNS | 7 | 0.37 | 46 | 0.18 | 12 | 0.05 | 6 | 0.50 | ND | ND |
| *Providencia rettgeri* | 1 | 0.05 | 43 | 0.17 | 9 | 0.03 | 6 | 0.67 | 0 | 0.00 |
| *Proteus vulgaris* | 0 | 0.00 | 37 | 0.14 | 3 | 0.01 | 1 | 0.33 | 3 | 0.08 |
| *Klebsiella pneumoniae* | 2 | 0.11 | 28 | 0.11 | 7 | 0.03 | 3 | 0.43 | 0 | 0.00 |
| *Pseudomonas other* | 2 | 0.11 | 24 | 0.09 | 10 | 0.04 | 6 | 0.60 | 0 | 0.00 |

| | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| *Klebsiella oxytoca* | 0 | 0.00 | 16 | 0.06 | 3 | 0.01 | 0 | 0.00 | 2 | 0.12 |
| *Serratia marsescens* | 1 | 0.05 | 14 | 0.05 | 2 | 0.01 | 2 | 1.00 | 0 | 0.00 |
| *Enterobacter aerogenes* | 2 | 0.11 | 8 | 0.03 | 0 | 0.00 | 0 | NA | 1 | 0.12 |
| Other | 1 | 0.05 | 3 | 0.01 | 1 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| GBS | 2 | 0.11 | 2 | 0.01 | 0 | 0.00 | 0 | NA | ND | ND |

Misc, Gram-positive bacteria that were PYR-negative, Catalase-negative, and Streptex-negative; MSSA, methicillin-sensitive *Staphylococcus aureus*; MRSA, methicillin-resistant *Staphylococcus aureus*; CNS, coagulase-negative *Staphylococcus*; *Pseudomonas other*, Gram-negative bacteria with good identification to genus via API-20E but were not *P. aeruginosa*; GBS, Group B *Streptococcus*; Other, any Gram-negative organism that could not be identified by API-20E.

[a] Number of baseline urine specimens with organism divided by the total number of baseline urines

[b] Number of patient-weeks the organism was detected divided by total number of patient-weeks

[c] Number of new acquisitions of the organism divided by total number of patient-weeks

[d] Number of episodes lasting only one week divided by the number of new episodes (excluding the first and last study visits)

[e] Number of isolates of the organism that were resistant to at least one antimicrobial divided by the total number of isolates of that organism

824    **Table 5.** Prevalence of antimicrobial resistant isolates

| Organism | Resistance | [a]Participant Prevalence | [b]Organism Prevalence |
|---|---|---|---|
| *Staphylococcus aureus* (13 participants, 168 isolates) | Methicillin | 9 (69) | 81 (48) |
| *Proteus mirabilis* (11 participants, 118 isolates) | Ciprofloxacin | 7 (64) | 81 (69) |
| *Providencia stuartii* (9 participants, 111 isolates) | Ciprofloxacin | 4 (44) | 27 (24) |
| | ESBL | 1 (11) | 22 (20) |
| *Morganella morganii* (5 participants, 64 isolates) | Ciprofloxacin | 2 (40) | 24 (37) |
| *Escherichia coli* (8 participants, 89 isolates) | Ciprofloxacin | 1 (12) | 26 (29) |
| *Pseudomonas aeruginosa* (8 participants, 66 isolates) | Ciprofloxacin | 3 (37) | 10 (15) |
| | ESBL | 2 (25) | 12 (18) |
| *Proteus vulgaris* (3 participants, 37 isolates) | Ciprofloxacin | 2 (67) | 3 (8) |
| *Klebsiella oxytoca* (3 participants, 16 isolates) | ESBL | 1 (33) | 2 (12) |
| *Enterobacter aerogenes* (2 participants, 8 isolates) | ESBL | 1 (50) | 1 (12) |

825    [a]Number (percent) of study participants colonized by the organism with isolates resistance to the
826    listed antimicrobial

827    [b]Number (percent) of isolates of the organism that were resistant to the listed antimicrobial

828    **Table 6.** Colonization Dynamics

| Participant | Number of events | Isolates lost[a] | Isolates re-gained[b] | New isolates[c] | New ARO[d] | Incidence of new ARO[e] | Net change[f] |
|---|---|---|---|---|---|---|---|
| Catheter Changes | | | | | | | |
| A | 7 | 7 | 4 | 6 | 0 | NA | +3 |
| B | 5 | 1 | 0 | 0 | 1 | 0.17 | -1 |
| C | 11 | 12 | 11 | 9 | 1 | 0.11 | +8 |
| D | 2 | 0 | 0 | 1 | 0 | NA | +1 |
| E | 2 | 2 | 0 | 5 | 1 | 1.00 | +3 |
| G | 7 | 4 | 4 | 1 | 2 | 0.40 | +1 |
| H | 4 | 2 | 1 | 0 | 0 | 0.00 | -1 |
| I | 2 | 0 | 0 | 1 | 0 | NA | +1 |
| *Average* | 5.0 | 3.5 | 2.5 | 2.9 | 0.6 | 0.28 | +1.9 |
| Antimicrobial Treatments | | | | | | | |
| B | 1 | 5 | 3 | 2 | 0 | 0.00 | 0 |
| F | 1 | 1 | 0 | 2 | 0 | 0.00 | +1 |
| G | 1 | 2 | 1 | 1 | 1 | 0.50 | 0 |
| *Average* | 1.0 | 2.7 | 1.3 | 1.7 | 0.3 | 0.17 | +0.3 |

[a] Number of isolates present the week prior to the event and absent the week following the event

[b] Number of isolates that were lost due to the event but reemerged in the subsequent three weeks

[c] Number of isolates that were not present the week prior to the event but emerged in the
subsequent three weeks

[d] Number of new isolates that were antimicrobial resistant organisms (AROs)

[e] Number of new ARO acquisitions divided by total number of new acquisitions

[f] Net impact of the event on the number of isolates detected in the participants weekly urine
samples

NA, Not applicable

**Figure 1. Epidemiology and dynamics of catheter-associated bacteriuria.** Culture results for each study participant (letters) at each

study visit (numbers, starting with 0 for baseline) are presented. White circles with light gray outlines indicate study visits at which a

urine specimen could not be obtained. The white circle with a black outline indicates the only culture-negative urine sample

(participant G, week 19). #IDSA CAUTI definition criteria met; [] caregiver-diagnosed CAUTI; *antimicrobial use; ^catheter change;

Misc, Gram-positive bacteria that were PYR-negative, Catalase-negative, and Streptex-negative; MSSA, methicillin-sensitive

*Staphylococcus aureus*; MRSA, methicillin-resistant *Staphylococcus aureus*; CNS, coagulase-negative *Staphylococcus*; *Pseudomonas*

other, Gram-negative bacteria with good identification to genus via API-20E but were not *P. aeruginosa* by PCR; GBS, Group B

*Streptococcus*; Other, any Gram-negative organism that could not be identified by API-20E.